Eckert & Ziegler Strahlen und Medizintechnik AG
F:EUZ
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.34
22.8167
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Eckert & Ziegler Strahlen und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Revenue Growth: Eckert & Ziegler's revenue grew by 4% in the first nine months of 2025, with FX-adjusted growth closer to 7%, mainly driven by strong radiopharmaceutical sales.
Profitability: Adjusted EBIT rose by nearly 10%, and net income increased by 28% compared to last year; gross margin improved by 2 percentage points to 48%.
Medical Segment Strength: The Medical business posted almost 15% sales growth and significant gross and EBIT margin improvements, supported by GalliaPharm and CDMO contributions.
Isotope Segment Recovery: The Isotope segment had a weak first half but saw improved Q3 sales (up 4% YoY), though overall segment revenue remained 6% below last year.
Regional Performance: Asia, especially China and Japan, was a highlight with 16% of total revenue and strong growth, validating recent investments.
Guidance Reaffirmed: Management remains confident in achieving full-year guidance: EUR 320 million net sales and approximately EUR 78 million adjusted EBIT, but notes that license income recognition in Q4 is key.
Capacity & Expansion: GalliaPharm production capacity is below 100%; new facilities in Berlin and China are on schedule, with major expansions expected to be ready by 2027–2028.
CDMO & CapEx: CDMO revenues are growing with recurring business, and annual CapEx is expected around EUR 20 million; larger investments for actinium production are postponed pending demand clarity.
